Standout Papers

LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in co... 2006 2026 2012 2019 959
  1. LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia (2006)
    Julia Skokowa, Gunnar Cario et al. Nature Medicine
  2. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer (2014)
    Ali Afshar‐Oromieh, Frederik L. Giesel et al. European Journal of Nuclear Medicine and Molecular Imaging
  3. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer (2013)
    Ali Afshar‐Oromieh, Christian M. Zechmann et al. European Journal of Nuclear Medicine and Molecular Imaging
  4. 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging (2012)
    Matthias Eder, Martin Schäfer et al. Bioconjugate Chemistry
  5. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer (2015)
    Martina Benešová, Martin Schäfer et al. Journal of Nuclear Medicine
  6. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 (2016)
    Clemens Kratochwil, Frederik L. Giesel et al. Journal of Nuclear Medicine
  7. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients (2017)
    Ali Afshar‐Oromieh, Tim Holland‐Letz et al. European Journal of Nuclear Medicine and Molecular Imaging
  8. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions (2015)
    Ali Afshar‐Oromieh, Clemens Kratochwil et al. Journal of Nuclear Medicine
  9. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer (2014)
    Matthias Eder, Oliver Neels et al. Pharmaceuticals
  10. [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer (2022)
    Ute Hennrich, Matthias Eder Pharmaceuticals

Immediate Impact

7 by Nobel laureates 28 from Science/Nature 81 standout
Sub-graph 1 of 18

Citing Papers

Radiochemistry for positron emission tomography
2023 Standout
In vivo hematopoietic stem cell modification by mRNA delivery
2023 StandoutScienceNobel
93 intermediate papers

Works of Matthias Eder being referenced

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo
2019
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
2015 Standout
and 30 more

Author Peers

Author Last Decade Papers Cites
Matthias Eder 1598 5724 5934 3263 191 12.9k
Javid J. Moslehi 1121 1455 2083 6225 206 15.2k
Christian Peschel 3108 1660 3052 5142 341 16.6k
David G. Kirsch 298 1577 3720 3980 257 13.0k
David F. Jarrard 403 1268 4832 2078 203 9.7k
Anders Bjartell 363 1639 7069 2466 340 13.1k
Silke Gillessen 353 1337 4257 3195 253 9.6k
William Kevin Kelly 818 1854 6118 3777 240 11.7k
William H. McBride 399 3357 2740 6513 301 16.7k
Albert F. LoBuglio 882 2622 1068 2827 189 9.4k
Manish Kohli 840 2052 6578 2486 218 10.7k

All Works

Loading papers...

Rankless by CCL
2026